Table 2.
Comparison of the inflammatory molecule levels in COVID-19 patients with headache regarding pulmonary involvement
| COVID-19 Patients with Headache (n = 48) | |||||
|---|---|---|---|---|---|
| Pulmonary Infiltration (n = 31) 65% |
Without Pulmonary Infiltration (n = 17) 35% |
||||
| Mean ± SD |
Median (Q1-Q3) |
Mean ± SD |
Median (Q1-Q3) |
Pvalue | |
| NLRP3 (ng/mL) | 3.03 ± 3.92 | 1.43 (1.15–3.32) | 3.18 ± 4.91 | 1.53 (1.11–2.70) | 0.982 |
| IL-6 (pg/mL) | 141.63 ± 126.2 | 100.09 (26.04–217.05) | 34.13 ± 18.83 | 31.84 (20.70–48.39) | 0.036 |
| IL-10 (pg/mL) | 18.12 ± 12.46 | 13.58 (10.98–20.24) | 14.96 ± 6.37 | 12.72 (10.40–19.66) | 0.283 |
| Ang II (pg/mL) | 416.22 ± 188.78 | 366.45 (267.33–524.59) | 471.62 ± 165.93 | 443.07 (401.79–514.73) | 0.111 |
| ACE2 (ng/mL) | 11.65 ± 5.40 | 10.71 (7.36–15.72) | 9.02 ± 3.63 | 8.93 (7.39–10.60) | 0.073 |
| HMGB1 (pg/mL) | 960.17 ± 318.71 | 964.87 (724.42–1205.49) | 707.48 ± 294.84 | 759.38 (485.12–923.55) | 0.012 |
| D-dimer (μg/mL) | 10.26 ± 8.00 | 7.20 (5.50–13.90) | 5.05 ± 2.82 | 4.90 (2.90–6.80) | 0.011 |
| CGRP (pg/mL) | 86.13 ± 139.05 | 34.72 (25.02–67.22) | 208.48 ± 290.35 | 55.46 (20.92–287.63) | 0,321 |
Q1: Lower Quartile; Q3: Upper Quartile